MedPath

Imipenem and Cilastatin

These highlights do not include all the information needed to use Imipenem and Cilastatin for Injection, USP (I.V.) safely and effectively. See full prescribing information for Imipenem and Cilastatin for Injection, USP (I.V.). IMIPENEM AND CILASTATIN FOR INJECTION, USP, for intravenous use Initial U.S. Approval: 1985

Approved
Approval ID

0a1dd9b9-ada1-4bff-9dcb-18961254e9e8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 10, 2022

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Imipenem and Cilastatin Sodium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-349
Application NumberANDA090577
Product Classification
M
Marketing Category
C73584
G
Generic Name
Imipenem and Cilastatin Sodium
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 1, 2020
FDA Product Classification

INGREDIENTS (3)

SODIUM BICARBONATEInactive
Quantity: 10 mg in 20 mL
Code: 8MDF5V39QO
Classification: IACT
IMIPENEMActive
Quantity: 250 mg in 20 mL
Code: 71OTZ9ZE0A
Classification: ACTIM
CILASTATIN SODIUMActive
Quantity: 250 mg in 20 mL
Code: 5428WXZ74M
Classification: ACTIM

Imipenem and Cilastatin Sodium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-322
Application NumberANDA090577
Product Classification
M
Marketing Category
C73584
G
Generic Name
Imipenem and Cilastatin Sodium
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 1, 2020
FDA Product Classification

INGREDIENTS (3)

SODIUM BICARBONATEInactive
Quantity: 20 mg in 20 mL
Code: 8MDF5V39QO
Classification: IACT
IMIPENEMActive
Quantity: 500 mg in 20 mL
Code: 71OTZ9ZE0A
Classification: ACTIM
CILASTATIN SODIUMActive
Quantity: 500 mg in 20 mL
Code: 5428WXZ74M
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Imipenem and Cilastatin - FDA Drug Approval Details